| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -5,178 | 1,585 | -7,448 | -20,739 |
| Depreciation and amortization | 566 | 678 | 80 | 200 |
| Foreign withholding tax receivable | NaN | 0 | 0 | 1,899 |
| Stock-based compensation | 48 | 610 | 1,533 | 2,601 |
| Decrease in the carrying amount of right-of-use-assets | 363 | 528 | 516 | 1,478 |
| (gain) on lease termination | 61 | NaN | -51 | 0 |
| Amortization of premium/discount on purchased securities | NaN | -30 | -182 | NaN |
| Loss (gain) on fixed asset disposal | NaN | -31 | NaN | NaN |
| Amortization of debt issuance costs | 0 | 9 | 10 | 18 |
| Accretion of final payment on term loans | 0 | 32 | 33 | 65 |
| Account receivable | -195 | 5,159 | -145 | -413 |
| Prepaid expenses and other current assets | 880 | -1,194 | 764 | 1,545 |
| Deposits | 62 | 655 | 12 | 458 |
| Other payable | 314 | 499 | 1 | 189 |
| Other assets | NaN | NaN | NaN | 184 |
| Accounts payable | -622 | 1,601 | -1,280 | 804 |
| Accrued expenses | -112 | -259 | 352 | -1,390 |
| Research and development contract liability | -5,335 | -2,481 | -1,763 | 9,494 |
| Operating lease liability | -353 | -518 | -504 | -1,550 |
| Net cash used in operating activities | -10,942 | -1,076 | -9,024 | -11,587 |
| Purchases of property and equipment | 121 | 0 | 0 | 177 |
| Cash received from the sale of property and equipment | NaN | 20 | 20 | NaN |
| Purchases of marketable securities | NaN | 0 | 16,288 | NaN |
| Redemption of marketable securities | NaN | -7,000 | -9,500 | NaN |
| Net cash used in investing activities | -121 | 7,020 | -6,768 | -177 |
| Proceeds from issuance of common stock, warrants and pre-funded warrants, net of transaction costs | NaN | 10,243 | 0 | 18,046 |
| Proceeds from atm offering, net of sales agent commissions and fees | 306 | 749 | 1,001 | 752 |
| Repayment of term loans | 0 | -1,500 | -1,000 | -2,000 |
| Issuance of common stock upon exercise of warrants and pre-funded warrants, net | NaN | 0 | NaN | NaN |
| Net cash provided by (used in) financing activities | 306 | 9,492 | 1 | 16,798 |
| Net decrease in cash, cash equivalents, and restricted cash | -10,757 | 15,436 | -15,791 | 5,034 |
| Cash, cash equivalents, and restricted cash at beginning of period | 27,290 | 11,854 | 22,611 | NaN |
| Cash, cash equivalents, and restricted cash at end of period | 16,533 | 27,290 | 11,854 | NaN |
Cue Biopharma, Inc. (CUE)
Cue Biopharma, Inc. (CUE)